Objective: Earlier studies pointed out that the high density lipoprotein (HDL)-associated paraoxonase (PON) activity was decreased in patients with hyperlipidaemia compared with healthy age-matched controls. PON can inhibit low density lipoprotein (LDL) oxidation and has an antiatherogenic effect. The aim of the present study was to evaluate the effect of gemfibrozil on serum PON and lipoprotein levels in patients with hyperlipidaemia. Patients and Methods: 57 patients with hypertriglyceridaemia were enrolled in the study (26 males, 31 females). The mean (± SD) body mass index was 26.17 ± 6.17 kg/m2. The effects of twice daily gemfibrozil 600 mg on serum cholesterol, lipoproteins, triglyceride, apolipoproteins and fibrinogen levels as well as on liver and kidney function were measured. Serum PON activity was determined spectrophotometrically using paraoxon as substrate. Results: Following treatment with gemfibrozil for 3 months, serum triglyceride and cholesterol levels were significantly decreased (from 4.01 ± 1.95 to 2.69 ± 1.61 mmol/L, p < 0.003 and from 7.44 ± 2.45 to 6.22 ± 0.96 mmol/L; p < 0.05, respectively), while the protective HDL level was not significantly increased. Furthermore, the low density lipoprotein (LDL) level was not significantly decreased while the apolipoprotein B-100 level was significantly reduced (from 1.36 ± 0.29 to 1.28 ± 0.22 g/L; p < 0.05), and apolipoprotein AI remained unchanged. The serum PON activity was significantly increased (from 220 ± 98 to 253 ± 100 U/L; p < 0.001). Standardised values for HDL (PON/HDL) were also significantly increased (from 190 ± 85 to 235 ± 104; p < 0.01). Conclusions: Gemfibrozil has a lipid-lowering effect in hypertriglyceridaemic patients and may improve the antioxidant status by increasing serum PON activity.
ASJC Scopus subject areas
- Pharmacology (medical)